DNA damage repair in breast cancer and its therapeutic implications

Area of Science:

• Genetics and Genomics
• Oncology
• Molecular Biology

Background:

• The DNA damage response (DDR) is vital for repairing DNA lesions and maintaining genomic stability, preventing cancer formation.
• Mutations in DDR genes like BRCA1/2, PTEN, and P53 are linked to various breast cancer subtypes.
• These mutations can sensitize cancer cells to specific DDR inhibitors, such as PARP inhibitors for BRCA1/2-mutated cancers.

Purpose of the Study:

• To review specific DNA damage response defects in breast cancer.
• To present the developmental status of various DDR inhibitors for breast cancer treatment.

Main Methods:

• Literature review of DNA damage response mechanisms in breast cancer.
• Analysis of current clinical development of DDR inhibitors.
• Discussion of mono- and combination therapy strategies.

Main Results:

• Specific DDR defects contribute to breast cancer pathogenesis.
• Several DDR inhibitors, including PARP, ATM/ATR, and DNA-PK inhibitors, are in development.
• These inhibitors show potential in both monotherapy and combination treatments for breast cancer.

Conclusions:

• Understanding DDR defects is key to targeted breast cancer therapy.
• DDR inhibitors represent a promising therapeutic avenue for breast cancer.
• Further research into DDR inhibitor combinations may enhance treatment efficacy.